EDMONTON, ALBERTA--CV Technologies Inc. (TSX-VEN:CVQ) today announced the launch of its newest HerbTech (R) product NURITE-FX.NURITE-FX is the first product brought to the consumer market by CV Technologies with a DIN (Drug Identification Number: No 02240778). Initially NURITE-FX will be available at progressive Health Food stores and the Real Canadian Superstore. Health Canadaassigns a DIN to each drug approved for use in Canada. NURITE-FX'sclaim, as approved by Health Canada, is:
"To help temporarily restore mental alertness or wakefulness when experiencing fatigue or drowsiness"
NURITE-FX is a unique patented extract from North American Ginsengdeveloped by CV Technologies using its proprietary ChemBioPrint(TM) technology. It has undergone many years of rigorous scientific testing. The studies have shown increased alertness, improved memory, learning and concentration. The ChemBioPrint(TM) technology is unique in the natural health industry and provides the highest level of assurance to consumers in effectiveness and safety. In fact, Health Canada allows the claim "Batch to batch guaranteed by consistent chemical and biological profile."
According to Kim Lucas, CVT's president & CEO, "The launch of NURITE-FX marks a new high point for CV Technologies: introducing our first DIN product on the market. Moreover, the claims allowed by Health Canada for this product are unique and extremely powerful. It also marks one of the first times that such a strong DIN claim has been allowed by Health Canada for a natural health product. This claim reflects the stringent quality standards CVT has put behind the product."
CV Technologies, Inc.'s vision is to empower personal wellness by becoming a global leader in the development, distribution, marketing and selling of safe and effective natural substances fordisease prevention and health management. More information about CV Technologies, Inc. can be found at www.cvtechnologies.com and www.sedar.com
This news release contains forward-looking statements that involverisks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to, the need for capital, changing market conditions, completion of clinical trials, patient enrolment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's filings with Canadian securities authorities.